385 related articles for article (PubMed ID: 28842263)
21. Didehydro-Cortistatin A: a new player in HIV-therapy?
Mousseau G; Valente ST
Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
[TBL] [Abstract][Full Text] [Related]
23. A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG).
Huang H; Kong W; Jean M; Fiches G; Zhou D; Hayashi T; Que J; Santoso N; Zhu J
Nucleic Acids Res; 2019 Aug; 47(14):7333-7347. PubMed ID: 31165872
[TBL] [Abstract][Full Text] [Related]
24. A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency.
Röling M; Mollapour Sisakht M; Ne E; Moulos P; Crespo R; Stoszko M; De Crignis E; Bodmer H; Kan TW; Akbarzadeh M; Harokopos V; Hatzis P; Palstra RJ; Mahmoudi T
mBio; 2021 Dec; 12(6):e0298021. PubMed ID: 34872356
[TBL] [Abstract][Full Text] [Related]
25. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
26. LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds.
Jung U; Takahashi M; Rossi JJ; Burnett JC
Methods Mol Biol; 2016; 1354():255-64. PubMed ID: 26714717
[TBL] [Abstract][Full Text] [Related]
27. HIV "shock and kill" therapy: In need of revision.
Abner E; Jordan A
Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
[TBL] [Abstract][Full Text] [Related]
28. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
29. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
Macías D; Oya R; Saniger L; Martín F; Luque F
Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
[TBL] [Abstract][Full Text] [Related]
30. The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.
Alto A; Natesampillai S; Chandrasekar AP; Krogman A; Misra A; Shweta F; VanLith C; Yao JD; Cummins NW; Badley AD
J Virol; 2021 May; 95(12):. PubMed ID: 33827940
[TBL] [Abstract][Full Text] [Related]
31. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.
Sánchez-Duffhues G; Vo MQ; Pérez M; Calzado MA; Moreno S; Appendino G; Muñoz E
Curr Drug Targets; 2011 Mar; 12(3):348-56. PubMed ID: 20955147
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580.
Alamer E; Zhong C; Liu Z; Niu Q; Long F; Guo L; Gelman BB; Soong L; Zhou J; Hu H
J Virol; 2020 May; 94(11):. PubMed ID: 32188727
[TBL] [Abstract][Full Text] [Related]
33. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
[TBL] [Abstract][Full Text] [Related]
34. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
35. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.
Kessing CF; Nixon CC; Li C; Tsai P; Takata H; Mousseau G; Ho PT; Honeycutt JB; Fallahi M; Trautmann L; Garcia JV; Valente ST
Cell Rep; 2017 Oct; 21(3):600-611. PubMed ID: 29045830
[TBL] [Abstract][Full Text] [Related]
37. Specific Activation
Li G; Zhang Z; Reszka-Blanco N; Li F; Chi L; Ma J; Jeffrey J; Cheng L; Su L
J Virol; 2019 Jun; 93(12):. PubMed ID: 30971469
[TBL] [Abstract][Full Text] [Related]
38. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types.
Blanco A; Mahajan T; Coronado RA; Ma K; Demma DR; Dar RD
Viruses; 2021 Jun; 13(6):. PubMed ID: 34201394
[TBL] [Abstract][Full Text] [Related]
40. Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.
Venkatachari NJ; Zerbato JM; Jain S; Mancini AE; Chattopadhyay A; Sluis-Cremer N; Bar-Joseph Z; Ayyavoo V
Retrovirology; 2015 Oct; 12():85. PubMed ID: 26438393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
